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(cT2cN0). 25 (75.8%) presented invasive ductal BC and 4 (12.1%) invasive lobular BC. 32 (97%) patients were positive estrogen
receptor status.
Results. The median age was 66.15 (range 52–85) with an average follow up of 24 months (range 2–47). The pathologic stage were
Stage I in 24 cases (72.7%) and 9 cases (27.3%) Stage II. Dose were 2100 cGy (63.6%) as exclusive treatment, Good GEC-ESTRO
candidates 90.4%, and 1000 cGy (36.4%) as complementary treatment . Electron energies ranged from 6MeV to 12MeV, most
frequently selected were 6 (72.7%). Applicator diameter used ranged from 5 to 6 cm (5 cm, 90.9%). Beveled end of 0◦, 15◦, and 30◦
were 27.3%, 33.3% and in 39.4%, respectively. We used metallic internal patient-shielding in all procedures. The time needed for
a complete healing of the wound was less than 15 days in 78.8% of the cases. Cosmetics results according to NSABP/RTOG scale,
were excellent in 4 (12.1%), good in 16 (48.5%) and fair in 6 (18.2%). We observed a liponecrosis in 7 patients (21.2%). As regards
local control, there was no local relapse. The global survival was 97%.
Conclusions. The IORT with electrons in selected patients, requiring transportation, is an attractive accelerated partial breast
irradiation technique, secure, repeatable with limited complications and good cosmetic outcomes.
http://dx.doi.org/10.1016/j.rpor.2013.03.103
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Objective. To analyze local recurrence in patients with breast cancer with positive or close margin (<2mm) treated with conser-
vative surgery plus radiation therapy at our Center.
Materials and methods. Retrospective analysis of 157/1046 patients with breast cancer stages I and II, treated with conservative
surgery plus radiation therapy from January 1993 to December 2009. Median age: 54 years (24–88). 53% of the patients (pts) were
stage I and 47% stage II. 90%were inﬁltrating ductal carcinoma. 22% of the ptswere histological grade I, 42% grade II and 22% grade
III. The most frequent molecular subtype was luminal A (51%). 108 (69%) of the pts received adjuvant chemotherapy, medium
cycle 6 (0–16), with anthracyclines (32%), and anthracycline–taxanes (17%). 80% received hormone therapy. All patients were
treated with 50 Gy radiation therapy to the whole breast in 25 fractions± regional nodes with or without a boost to the primary
tumor bed of 16–20Gy in fractions 8–10. Kaplan–Meier curves have been used for the statistical analysis of survival. Prognostic
factors such as age, tumor size, surgery, histology, grade, hormonal and chemotherapy treatment have been associated with local
failure-free survival and overall survival (Cox regression).
Results. With a median follow-up of 89 months (19–268 months) 4 patients developed local recurrence as a ﬁrst site of failure.
At 22 years the local recurrence-free survival and overall survival were 92.9% and 76.3% respectively. Of the prognostic factors
analyzed only hormonal treatment has been associated signiﬁcantly with overall survival (p=0.02).
Conclusions. In our experience the presence of a positive or closed margin (<2mm) in patients with breast cancer treated with
conservative surgery plus radiation therapy, was not associated with a high rate of local failure, and although in the presence
of positive margin a widening of this margin is recommended, radiation therapy seems to be a safe option in those patients in
which enlargement is not possible.
http://dx.doi.org/10.1016/j.rpor.2013.03.104
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Objective. We present a case of a breast cancer (BC) patient undergoing radiotherapy with an AP, when very low doses of radiation
were delivered.
Case report. A 52-year-old woman, pre-menopausal, diagnosed of left BC. She underwent MRM+ALND. Histological examination:
DIC of 3.2 cm., GIII, vascular-lymphatic invasion (+), surgical margins (−), HR (+), HER-2/neu (+), 2/12 axillar lymph nodes. Received
adjuvant CHT [ACx4 followed by Paclitaxel +Trastuzumab (×12 weeks/for 1 year of Trastuzumab)]. We scheduled adjuvant 3DRT
with 15MV photons, total dose of 50.4Gy/1.8Gy/fr, to left chest wall and ipsilateral supraclavicular nodes. When 7.2Gy were
delivered, she was admitted in ER presenting acute retrosternal chest pain, partially improved with sublingual nitroglycerin,
exacerbated with deep breathing and decubitus position. EKG showed elevation of ST from V3 to V6. With the diagnostic of
ischemic cardiopathy versus pulmonary thromboembolism, cardiac markers, angio-TAC and cardiac catheterization discarded
ischemic disease. The rest of her ER staywas asymptomatic andwasdischarged. Five days after, thepatient resumed radiotherapy.
During the treatment she had new episode of thoracic pain solved with NSAIDs and rest. The clinical picture was attributed to
radiation-induced AP. She continued with radiotherapy and NSAIDs, remaining asymptomatic until its completion.
Discussion. Less than 1% of cases of AP are chest-wall radiation involved. When presented during RT, mimic a nonspeciﬁc peri-
carditis with chest pain, fever and/or nonspeciﬁc EKG abnormalities. Its treatment is rest and NSAIDs± colchicine. Standard
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constraints of heart dosimetry (V45<50%, V60<30%, heart mean dose<20Gy) predict late damage; do not predict AP. Therefore
it could be considered a side-effect non-dose-dependent.
Conclusions. AP is a rare complication of BC radiotherapy treatment and its diagnosis is clinical. Because it can occur with very
low doses, it should be considered in the differential diagnosis of all chest pain episodes in BC patients undergoing radiotherapy,
regardless the dose administered at its onset.
http://dx.doi.org/10.1016/j.rpor.2013.03.105
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Introduction. Radiotherapy is the standard treatment after breast conserving surgery (BCS) in early-stage breast cancer. There is
evidence that an additional boost in tumor bed decreases the risk of local recurrence. However, there is not an ideal method
of radiation delivering. New technologies have improved accuracy on irradiation of malignancies in order to not injure normal
tissues (i.e. IGRT) Non-invasive breast brachitherapy (NIBB), AccuBoost, is our new system at ICO.
Purpose. Implementation of NIBB since April 2012. We have started a Phase II trial to evaluate the feasibility, toxicity and local
control of AccuBoost in patients with early-stage breast cancer.
Materials and methods. AccuBoost system applies breast brachytherapy without invasive catheters, and with mammographic
image guidance using stereotactic localization for tumor bed boost. AcuuBoost applicators are selected by radiation oncologist
who delimitates tumor bed (PTV) by mammography before each fraction delivery. From July 2012 to January 2013 we performed
56 treatments with AccuBoost.
Results. All patients underwent BCS before receiving RDT. Boost (16Gy) was delivered while WBRT (50Gy) administered. Repro-
ducibility of the tumor bed by mammography to be covered by AccuBoost applicators and good tolerance to compression in CC
and ML orientations were required. Tumor bed identiﬁcation required intraoperative clip placements to be deﬁned and also using
either seromas or postoperative changes. The mean CC and ML breast compressions were 5.1 and 6.1 cm, respectively. 35% of the
sessions were delivered using 6.0 round shape applicator. 27% were performed with 5.0 round shape and 5.3 D shape applicator.
Conclusion. NIBB is a unique and precise method of delivering HDR-photon irradiation to the tumor-bed tissue using mammo-
graphic image-guidance before each boost fraction delivery. AccuBoost allows a major optimization of external radiation units
and proﬁtability of HDR.
http://dx.doi.org/10.1016/j.rpor.2013.03.106
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Introduction. Skin is involved in most of radiotherapy (RT) treatments, however, systems to determinate the radiation-induced
skin toxicity are usually based on visual subjective rating scales. Radiation causes a vascular skin response which increases
as skin affectation increases. This response can be measured in order to obtain an objective assessment of radiation-induced
toxicity.
Objective. To establish a measurement system that allows us to quantify skin toxicity produced by RT.
Materials and methods. A laser Doppler ﬂowmeter (LDF), Periﬂux PF 3, has been used to measure in real time the cutaneous
microcirculation. 1824 measurements (912 in the irradiated area and 912 in the not irradiated area) have been performed aiming
to evaluate the cutaneous reaction over the irradiated skin area from patients of different pathologies undergoing RT. A baseline
measure for every measured point is taken before starting the RT treatment. Furthermore, to be able to observe the changes in
the microcirculation of the irradiated area with the delivered dose, several sets of measurements are taken at the same points
along the treatment and for one month after completing the RT treatment. At the same time, we performed a clinical assessment
of skin toxicity with the visual rating scale commonly used in RT.
Results. From the analysis of averaged measurements it can be observed a signiﬁcant increase of vascularization in the irradiated
area which increases with the administered dose. However, the measurements in the non-irradiated areas do not show a sig-
niﬁcant increase of vascularization. The measurements made once the treatment has ﬁnished show that microvascularization
decreases, tending to the baseline values.
